Table 4 Association of COL11A1 variant A with clinicopathological characteristics in breast cancer tissues
Presence or absence of variant A (qualitative) | Number of A copies (percentile: 50 th ) (quantitative) | Copies of variant A (for positive samples) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Clinical features | N (%) | Absence n (%) | Presence n (%) | Pearson χ 2 or Fisher’s exact | Ν (%) | Low | High | Pearson χ 2 or Fisher’s exact | Median | Mann–Whitney |
p-value | n (%) | n (%) | p-value | p-value | ||||||
Age Group | 0.060 | 1.000 | 0.420 | |||||||
< =50 years | 26 (35.6) | 22 (42.3) | 4 (19.0) | 4 (19.0) | 2 (16.7) | 2 (22.2) | 33,246 | |||
> 50 years | 47 (64.4) | 30 (57.7) | 17 (81.0) | 17 (81.0) | 10 (83.3) | 7 (77.8) | 99,636 | |||
Tumor Size | 0.912 | 1.000 | 0.941 | |||||||
≤ 2.0 cm | 59 (67.0) | 40 (66.7) | 19 (67.9) | 19 (67.9) | 10 (71.4) | 9 (67.9) | 96,274 | |||
> 2.0 cm | 29 (33.0) | 20 (33.3) | 9 (32.1) | 9 (32.1) | 4 (28.6) | 5 (35.7) | 38,092 | |||
Histopathological Type | 0.576 | 0.042 | 0.071 | |||||||
Lobular & rest | 18 (20.0) | 13 (21.7) | 5 (16.7) | 5 (16.7) | 0 (0.0) | 5 (33.3) | 108,055 | |||
Intraductal infiltrating | 72 (80.0) | 47 (78.3) | 25 (83.3) | 25 (83.3) | 15 (100.0) | 10 (66.7) | 69,402 | |||
Lymph-node Involvement | 0.825 | 0.683 | 0.500 | |||||||
Negative (Ν0) | 55 (67.1) | 38 (67.9) | 17 (65.4) | 17 (65.4) | 7 (58.3) | 10 (71.4) | 106,233 | |||
Positive (Ν+) | 27 (32.9) | 18 (32.1) | 9 (34.6) | 9 (34.6) | 5 (41.7) | 4 (28.6) | 37,995 | |||
Metastasis | 0.124 | 1.000 | 0.570 | |||||||
Negative M0 | 47 (85.5) | 32 (91.4) | 15 (75.0) | 15 (75.0) | 7 (70.0) | 8 (80.0) | 96,198 | |||
Positive M1 | 8 (14.5) | 3 (8.6) | 5 (25.0) | 5 (25.0) | 3 (30.0) | 2 (20.0) | 78,617 | |||
Grade | 0.352 | 0.683 | 0.328 | |||||||
Low (1–2) | 60 (73.2) | 42 (76.4) | 18 (66.7) | 18 (66.7) | 9 (60.0) | 9 (75.0) | 87,999 | |||
High (3) | 22 (26.8) | 13 (23.6) | 9 (33.3) | 9 (33.3) | 6 (40.0) | 3 (25.0) | 30,156 | |||
Estrogen-receptor Status | 0.269 | 0.109 | 0.059 | |||||||
Negative | 21 (23.9) | 12 (20.3) | 9 (31.0) | 9 (31.0) | 7 (46.7) | 2 (14.3) | 20,319 | |||
Positive | 67 (76.1) | 47 (79.7) | 20 (69.0) | 20 (69.0) | 8 (53.3) | 12 (85.7) | 100,602 | |||
Progesterone-receptor Status | 0.403 | 1.000 | 0.825 | |||||||
Negative | 46 (52.3) | 29 (49.2) | 17 (58.6) | 17 (58.6) | 9 (60.0) | 8 (57.1) | 89,068 | |||
Positive | 42 (47.7) | 30 (50.8) | 12 (41.4) | 12 (41.4) | 6 (40.0) | 6 (42.9) | 56,729 | |||
HER2 Overexpression Status | 0.257 | 1.000 | 0.254 | |||||||
Negative | 72 (81.8) | 51 (85.0) | 21 (75.0) | 21 (75.0) | 10 (71.4) | 11 (78.6) | 93,872 | |||
Positive | 16 (18.2) | 9 (15.0) | 7 (25.0) | 7 (25.0) | 4 (28.6) | 3 (21.4) | 31,872 | |||
TNBC, n (%) | 0.819 | 0.169 | 0.146 | |||||||
Yes | 17 (19.3) | 11 (18.6) | 6 (20.7) | 6 (20.3) | 5 (33.3) | 1 (7.1) | 90,085 | |||
No | 71 (80.7) | 48 (81.4) | 23 (79.3) | 23 (79.3) | 10 (66.7) | 13 (92.9) | 20,493 | |||